Tag: LimFlow
One-year outcomes from PROMISE I US study of LimFlow system published
LimFlow SA recently announced the publication of 12-month data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...
LimFlow receives Japan PMDA approval for clinical study of minimally-invasive technology
LimFlow announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification (CTN) for the Japanese cohort of...
Deep vein arterialisation should be considered in “no option” CLTI patients,...
Midterm results from a study of the largest population of patients with no-option chronic limb-threatening ischaemia (CLTI) treated with percutaneous deep vein arterialisation (pDVA)...
Positive two-year data from ALPS registry of LimFlow system published
LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialisation (pDVA) system. Results were...
First CLTI patient enrolled in PROMISE II pivotal study of LimFlow...
LimFlow, a specialist in minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), has announced...
PROMISE I trial affirms potential of LimFlow system for treatment of...
Initial findings of an early feasibility trial have demonstrated that the LimFlow System does represent a safe and reproducible method of treating patients with...
